Novartis to acquire Chinook Therapeutics for US$ 3.2 bn

Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease

Milla receives first cycle FDA approval for Dexmedetomidine Hydrochloride Injection

Zydus receives final approval from USFDA for Esomeprazole Magnesium

Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg and 40 mg had annual sales of USD 42 mn in the United States (IQVIA MAT April 2023)

Venus Remedies receives Ukrainian GMP approval for Its Carbapenem, Oncology parenteral facilities

The company expects this approval in Baddi to pave the way for GMP certifications from European Medicines Agency and other PIC/S member nations

Zydus receives final approval from the USFDA for Tadalafil Tablets USP

Tadalafil Tablets USP, 20 mg had annual sales of USD 61 mn in the United States (IQVIA MAT April 2023)

Brinton appoints Amit Jain as President & Head of Domestic Business

Jain will have oversight of Brinton's domestic operations, including business development, sales, and marketing

Piramal Critical Care appoints Jeffrey Hampton as President & COO

Hampton joins PCC from Accord Healthcare, where he was the President and responsible for accelerating the firm's growth strategy

USFDA approves Injectafer for the treatment of iron deficiency in adult patients with heart failure

Injectafer is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency

Unimed to expand operations into Singapore with Marine Pharma merger

Establishes distribution center in top hub for international shipping

Keytruda+ chemotherapy improves overall survival versus chemotherapy alone for unresectable advanced pleural mesothelioma

In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone